KLOW peptide: what is in the GLOW and KLOW blends, and what the evidence shows

What is the difference between GLOW and KLOW?

The difference is one ingredient, KPV. An August 2026 clinic page describes GLOW as GHK-Cu, BPC-157, and TB-500 in one vial. The same page describes KLOW as those three peptides plus KPV. It says GLOW is weighted toward skin regeneration and tissue repair.

The names have no fixed chemical definition. A wellness company's guide uses GLOW for a compounded injectable mix of GHK-Cu, glutathione, and vitamin C (ascorbic acid). That guide says the product is also marketed as Klow. It lists no BPC-157 or TB-500.

The sources reviewed show no standard amount or ratio for the peptides in either blend. A label that gives one total for the whole vial says nothing about each peptide's share. The ingredient list and amounts on the exact vial are the first record to read.

What FDA and study records say about each ingredient

In 2026, FDA staff reviewed BPC-157, TB-500, and KPV for the 503A bulks list. That is FDA's list of bulk substances that pharmacies may use to compound drugs under section 503A of federal law. Staff concluded that the criteria weigh against adding any of the three. Earlier nominations for all four peptides were withdrawn.

For sport, class S0 of the 2026 WADA Prohibited List bans at all times any substance with no current government approval for human therapeutic use. The list names BPC-157 in that class.

• GHK-Cu is a copper complex of a three-amino-acid peptide. Its human record found here is one small topical skin study. FDA's compounding safety-risk page lists injectable GHK-Cu among the withdrawn nominations, citing possible immune reactions (immunogenicity) and limited human data. WADA does not name GHK-Cu, though class S0 may apply.
• BPC-157 is a peptide of 15 amino acids, and FDA's 2026 briefing lists five small clinical studies of it. The largest assigned 53 people with ulcerative colitis, a long-term inflammation of the colon, by chance (randomized) to BPC-157 enemas or a placebo.
• In the BPC-157 colitis trial, the placebo was an inactive comparison, and an enema is a liquid given through the rectum. That trial appeared only as a meeting abstract, and FDA called its data inadequate to support efficacy and safety.
• A 2025 systematic review of BPC-157, a structured search of published studies, included 36 studies. Thirty-five were preclinical, meaning lab or animal work. The one clinical study was retrospective, meaning it looked back at past records. In it, 7 of 12 patients with chronic knee pain reported relief for more than 6 months after a knee injection.
• TB-500 is a seven-amino-acid piece of thymosin beta-4, capped at one end by an acetyl group, a small chemical unit. FDA's 2026 briefing found no clinical studies or human exposure data. A registry entry lists a placebo-controlled TB-500 study in people with stable artery disease as recruiting, with no posted results. WADA class S2 names it as a thymosin-β4 derivative.
• KPV is a three-amino-acid peptide (lysine, proline, valine). The best record found is cell and mouse work, such as a 2008 study where KPV in drinking water reduced colitis in mice. FDA found no human exposure data for KPV and reviewed it as a topical cream and gel. WADA does not name KPV, though class S0 may apply.

Has the KLOW or GLOW blend been tested in people?

No study of either blend in people was found in PubMed or ClinicalTrials.gov as of September 17, 2026. A PubMed search for BPC-157, TB-500, GHK-Cu, and KPV together returned no records. PubMed searches for KLOW peptide and GLOW peptide blend returned only unrelated papers.

Without KPV, a PubMed search for the other three peptides returned six records, all reviews of past research. On ClinicalTrials.gov, the public registry of planned and running studies, a search for KPV returned no entries. The entries for BPC-157, TB-500, and GHK-Cu each list only one of the four peptides.

What are the benefits of KLOW peptides?

The records searched show no benefit of the KLOW blend in people, since none tested the blend. A clinic page says KLOW may support skin regeneration and collagen synthesis, connective-tissue and wound repair, recovery capacity, gut barrier integrity, and lower inflammatory signaling. The records below cover single peptides.

The closest human record for skin is a 2006 randomized study of GHK-Cu skin-care products. Patients had laser resurfacing, a treatment that removes outer skin layers, around the mouth. Thirteen patients completed the study.

Blinded evaluators, who did not know each patient's group, found no faster fading of redness with GHK-Cu. At 12 weeks, wrinkles and skin quality improved in both groups, with no difference between them. Patients using GHK-Cu rated their skin quality higher on a questionnaire. That result applies to skin-care products on freshly treated skin.

BPC-157 has a few small human studies, mostly not of healing, and FDA found none for TB-500. For inflammation, the KPV record rests on cell and mouse colitis studies. None of the sources reviewed reports a fat-loss or weight result for either blend or any of its four peptides.

How strong is the evidence? The Peptide Field's peptide reviews grade BPC-157 and GHK-Cu as Emerging, meaning some studies in people exist and major questions remain. They grade TB-500 as Insufficient, meaning reliable studies in people are missing. No grade exists for either blend.

What are the side effects of KLOW peptide?

FDA's records describe risks for the single ingredients, and none describes side effects of the blend itself. Its safety-risk page says compounded BPC-157 and TB-500, for certain routes, and injectable GHK-Cu may pose a risk of immune reactions. It also names peptide-related impurities as a concern.

An immune reaction here means the body treats the peptide, or clumps of it, as foreign. FDA's briefings note that peptides with as few as two amino acids can form clumps (aggregate).

FDA searched its adverse event reports (FAERS) for BPC-157 through December 4, 2025, and found three. All three involved injected products. Two of the three also involved a second peptide: compounded thymosin in one and TB-500 in the other.

In the TB-500 case, a 40-year-old woman used a product labeled for research purposes only that held both peptides. She developed widespread darkened skin and darkened gums, and the reaction returned when she used the product again. FDA judged the reactions likely due to the product. With two peptides in it, FDA could not assess BPC-157's role.

FAERS searches found no reports for TB-500 through March 26, 2025, or for KPV through December 3, 2025. FDA states that reporting is voluntary and that FAERS data have limits. Pharmacies that compound under section 503A generally do not report adverse events to FDA. A licensed clinician can compare these records with a person's health history.

Is KLOW FDA-approved or allowed in compounding?

Neither KLOW nor GLOW is FDA-approved. FDA's 2026 briefings say BPC-157, TB-500, and KPV are not components of any FDA-approved drug. A vial containing them has no FDA label, approved use, or approved route.

On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee discussed BPC-157, KPV, TB-500, and MOTS-c for the 503A bulks list. PharmExec reported that the committee voted 8 to 6, with one member abstaining, in favor of adding BPC-157, KPV, and TB-500. ABC News reported the same count for BPC-157. GHK-Cu was not on the agenda.

The votes are nonbinding, meaning FDA does not have to follow them. PharmExec estimates that rulemaking would take eight to twelve months before pharmacies could compound them.

How to test a KLOW or GLOW label claim

Four questions test any claim made for a blend vial. Answer each one for the exact product, using a record you can name. If any answer is no or unknown, the claim is not established for that vial.

A certificate of analysis, a lab report for one batch, is the record for the first question. The Peptide Field's post on peptide testing explains what that report can show. A licensed clinician or pharmacist can review the answers with a person.

• Does the label list every ingredient and its amount, and does independent testing of that lot confirm each one? The sources reviewed show no standard amount for any peptide in KLOW or GLOW.
• Was this exact combination tested in people? For KLOW and GLOW, the searches described above turned up no such study.
• Did the study measure a health result in people, or only a lab or animal marker? Most records for these four peptides are lab, animal, or topical studies.
• Is each ingredient part of an FDA-approved drug for that use and route? For BPC-157, TB-500, and KPV, FDA's briefings answer no.